APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company’s business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities. Press release Presseaussendung
APEIRON Biologics AG (Apeiron) today announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH (Polymun) granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD) for treatment of various inflammatory conditions. Press release Presseaussendung
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and APEIRON Biologics AG today announced that they have entered into a collaboration to identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Press release Presseaussendung
Apeiron among the three finalists nominated for the EUROPEAN BIOTECHNICA AWARD 2010. Other finalists are listed companies Addex Pharmaceuticals (Switzerland) and Galapagos Genomics (Belgium).
Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS). Press release Presseaussendung
On Nov. 17th, one of our major shareholders, business angel and Chairman of the Supervisory Board, DDr. Manfred Reichl has received the award “Business Angel of the Year“. Congratulations!
